Journal article
A prospective cohort study comparing achieved anti-factor Xa peak levels in pregnant and non-pregnant patients receiving therapeutic-dose low-molecular-weight heparin
Abstract
Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in pregnant women. Enoxaparin is a low-molecular-weight heparin used during pregnancy to treat or prevent VTE. In this study, we compare anti-factor Xa peak levels in pregnant and non-pregnant women, and explore the association between anti-factor Xa (AFXa) peak levels and possible predictive parameters. Pregnant and non-pregnant patients received a therapeutic dose of …
Authors
Aleidan FAS; Aljarba GA; Aldakhil AA; Allehyani BI; Yahia MA; Alghtani NE; Badri M; Alaklabi AA; Alsuhaibani A; Crowther MA
Journal
International Journal of Hematology, Vol. 112, No. 1, pp. 1–7
Publisher
Springer Nature
Publication Date
July 2020
DOI
10.1007/s12185-020-02873-2
ISSN
0925-5710